Syquant Capital Sas Verona Pharma PLC Transaction History
Syquant Capital Sas
- $348 Million
- Q3 2025
A detailed history of Syquant Capital Sas transactions in Verona Pharma PLC stock. As of the latest transaction made, Syquant Capital Sas holds 1,208,312 shares of VRNA stock, worth $129 Million. This represents 37.01% of its overall portfolio holdings.
Number of Shares
1,208,312Holding current value
$129 Million% of portfolio
37.01%Shares
1 transactions
Others Institutions Holding VRNA
# of Institutions
302Shares Held
74.5MCall Options Held
992KPut Options Held
3.12M-
Janus Henderson Group PLC London, X06.13MShares$656 Million0.3% of portfolio
-
Perceptive Advisors LLC New York, NY5.51MShares$589 Million22.87% of portfolio
-
Darwin Global Management, Ltd. St. Helier, Y94.13MShares$441 Million16.48% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.38MShares$362 Million16.88% of portfolio
-
Rtw Investments, LP New York, NY3.05MShares$326 Million4.43% of portfolio
About Verona Pharma plc
- Ticker VRNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,954,200
- Market Cap $6.52B
- Description
- Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...